Global Cord Blood (NYSE:CO) Receives New Coverage from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Global Cord Blood (NYSE:CO) in a research report issued to clients and investors on Sunday. The firm set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Stock Performance

CO stock opened at $1.25 on Friday. The firm has a market cap of $151.94 million, a price-to-earnings ratio of 1.95 and a beta of 0.16. The firm has a 50-day simple moving average of $1.46 and a two-hundred day simple moving average of $1.36. Global Cord Blood has a one year low of $2.03 and a one year high of $5.50.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.